Grafalon

Grafalon is an intravenous anti‑T lymphocyte immunoglobulin (rabbit) preparation supplied as a prescription drug. The active ingredient is anti‑T lymphocyte immunoglobulin for human use, derived from rabbit antibodies. It is marketed in the European Union and is classified as an immunosuppressant. Grafalon is administered by intravenous infusion under medical supervision. The product is intended for use in transplant centers to reduce the risk of organ rejection and is provided in a sterile liquid form suitable for controlled dosing.

Grafalon is used primarily in the setting of organ transplantation to prevent early immune‑mediated graft injury and to facilitate successful engraftment.

- Prevention of acute cellular rejection in kidney, liver, heart, or lung transplants. - Induction therapy in combination with other immunosuppressive agents. - Treatment of steroid‑resistant rejection episodes. - Part of desensitization protocols for highly sensitized recipients. - Use in clinical trials evaluating novel transplant immunosuppression strategies. - Supportive therapy during peri‑operative period to reduce inflammatory activation.

The immunologic activity of Grafalon can produce a range of adverse reactions, most of which are related to its T‑cell depleting properties and infusion process.

Common: - Fever, chills, or rigors during or shortly after infusion. - Nausea, vomiting, or mild gastrointestinal discomfort. - Transient leukopenia or lymphopenia with mild infection risk. - Headache or mild dizziness.

Serious: - Severe infusion‑related reactions such as anaphylaxis or bronchospasm. - Cytokine release syndrome presenting with hypotension and organ dysfunction. - Opportunistic infections including viral, fungal, or bacterial pathogens due to profound immunosuppression. - Development of post‑transplant lymphoproliferative disorder (PTLD).

Because Grafalon produces profound and prolonged immunosuppression, careful patient assessment and monitoring are required before, during, and after therapy.

- Verify negative screening for active infections such as hepatitis B, C, HIV, and tuberculosis. - Assess baseline complete blood count and renal function prior to initiation. - Monitor vital signs and laboratory parameters closely during infusion. - Avoid use in patients with known hypersensitivity to rabbit proteins or murine antibodies. - Consider prophylactic antimicrobial agents to reduce risk of opportunistic infections.

Grafalon may interact with other medications that affect immune function or increase the risk of infusion‑related complications.

Avoid: - Concurrent use of other T‑cell depleting agents (e.g., antithymocyte globulin) without dose adjustment. - Live vaccines administered during or shortly after treatment.

Use with caution: - Calcineurin inhibitors (cyclosporine, tacrolimus) as combined immunosuppression may heighten infection risk. - Antimicrobial prophylaxis agents (e.g., trimethoprim‑sulfamethoxazole) requiring dose monitoring for additive toxicity. - Corticosteroids, which can amplify immunosuppressive effects and mask infection signs. - Anticoagulants, because infusion reactions may increase bleeding tendency.